Fig. 5

Identification of ctDNA variants with potential therapeutic actionability. Oncoprint showing mutated DNA damage repair (DDR) genes in ctDNA that were either predicted to confer response to platinum chemotherapy and/or PARP inhibition through in silico predictions (Cancer Genome Interpreter) (Biomarkers) or were identified within known DDR signalling pathways (Reactome) (Pathways). The percentage of altered cases is displayed to the right. Clinical characteristics of the cohort and enrichments for COSMIC mutational signatures associated with DDR, are shown on the bottom panels. Post-treatment plasma samples collected following platinum or other chemotherapies and/or radiation therapy, are indicated. DSBR, double strand break repair; MMR, mismatch repair; POLN, polymerase ν (nu) hypermutation